Nov 13, 2024
NeuroBo Pharmaceuticals to Participate in Investor Conferences in November
Nov 07, 2024
NeuroBo Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Oct 01, 2024
NeuroBo Pharmaceuticals to Participate in Investor Conferences in October
Aug 13, 2024
NeuroBo Pharmaceuticals Completes Enrollment of the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity
Aug 06, 2024
NeuroBo Pharmaceuticals Announces Joint Research Agreement, Together with Dong-A ST and ImmunoForge to Develop a Long-Acting Once-Monthly Formulation of DA-1726 for the Treatment of Obesity
Jun 25, 2024
NeuroBo Pharmaceuticals Announces the Closing of up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Jun 22, 2024
NeuroBo Pharmaceuticals' DA-1726 Demonstrated Superiority in Weight Loss, Retention of Lean Body Mass, and Lipid-Lowering Effects Compared to Survodutide, in Pre-Clinical Models
Mar 28, 2024
NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update
Mar 13, 2024
NeuroBo Pharmaceuticals Receives Safety Review Committee Approval to Continue With Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH
Feb 12, 2024
NeuroBo Pharmaceuticals to Participate in the BIO CEO & Investor Conference
Feb 01, 2024
NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity
Jan 18, 2024
NeuroBo Pharmaceuticals Reports Positive Pre-Clinical Safety Data of DA-1241 in Combination with Sitagliptin and Opens Enrollment for Part 2 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH
Jan 09, 2024
NeuroBo Pharmaceuticals Regains Compliance with Nasdaq Minimum Price Requirement
Jan 02, 2024
NeuroBo to Participate in Industry and Investor Conferences in January
Jan 21, 2021
NeuroBo Pharmaceuticals Closes $10.0 Million Private Placement
Jan 19, 2021
NeuroBo Pharmaceuticals Announces $10.0 Million Private Placement
Nov 13, 2020
NeuroBo Pharmaceuticals Reports Third Quarter 2020 Financial Results
Sep 02, 2020
NeuroBo Pharmaceuticals Appoints Douglas J. Swirsky to the Board of Directors
Aug 11, 2020
NeuroBo Pharmaceuticals Reports Second Quarter 2020 Financial Results
Jun 16, 2020
NeuroBo Pharmaceuticals to Join Russell 3000® and Microcap® Indexes